City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  70  Clinical trial(s) found  (Page 1 of 3 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 15335 ClinicalTrials.gov Number: NCT02614560

Principal Investigator: Ibrahim Aldoss, MD
Sponsor: Industrial

Title:  A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence with Allogeneic Hematopoietic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

COH Protocol Number: 15270 ClinicalTrials.gov Number: NCT02580552

Principal Investigator: Christiane Querfeld, MD, PhD
Sponsor: Industrial

Title:  A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type

COH Protocol Number: 15232 ClinicalTrials.gov Number: NCT02513472

Principal Investigator: Yuan Yuan, MD, PhD
Sponsor: Industrial

Title:  An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)

COH Protocol Number: 15223 ClinicalTrials.gov Number: NCT02614612

Principal Investigator: Haris Ali, MD
Sponsor: Industrial

Title:  A Randomized, Parallel-Cohort Phase 1 Study of INCB039110 in Combination With Corticosteroids for the Treatment of Acute Graft-Versus-Host Disease

COH Protocol Number: 15209 ClinicalTrials.gov Number: NCT02631044

Principal Investigator: Tanya Siddiqi, MD
Sponsor: Industrial

Title:  A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

COH Protocol Number: 15154 ClinicalTrials.gov Number: NCT02661022

Principal Investigator: Myo Htut, MD
Sponsor: Industrial

Title:  A Phase 1/2 Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

COH Protocol Number: 15140 ClinicalTrials.gov Number: NCT02509052

Principal Investigator: Michael Rosenzweig, MD
Sponsor: Institutional

Title:  A Phase I Dose-Escalation Trial of Leflunomide in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

COH Protocol Number: 15137 ClinicalTrials.gov Number: NCT02501473

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  Phase 1/2 Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin’s Lymphoma

COH Protocol Number: 15132 ClinicalTrials.gov Number: NCT02273739

Principal Investigator: Jasmine Zain, MD
Sponsor: Industrial

Title:  A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects with Advanced Solid Tumors, including Glioma, and with Angioimmunoblastic T-cell Lymphoma, that Harbor an IDH2 Mutation

COH Protocol Number: 15124 ClinicalTrials.gov Number: NCT02074839

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation

COH Protocol Number: 15123 ClinicalTrials.gov Number: NCT02520427

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

COH Protocol Number: 15116 ClinicalTrials.gov Number: NCT02089334

Principal Investigator: Sumanta Pal, MD
Sponsor: Industrial

Title:  A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma

COH Protocol Number: 15112 ClinicalTrials.gov Number: NCT02511184

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  A Phase 1B Study of Crizotinib in Combination with Pembrolizumab (MK-3475) in Patients with Untreated Advanced ALK-Translocated Non-Small Cell Lung Cancer

COH Protocol Number: 15070 ClinicalTrials.gov Number: NCT02418793

Principal Investigator: Nadia Ewing, MD
Sponsor: Industrial

Title:  A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics Profile of a Long-Acting Recombinant Factor VIIa (MOD-5014) in Adult Men with Hemophilia A or B

COH Protocol Number: 15060 ClinicalTrials.gov Number: NCT02318329

Principal Investigator: Joseph Chao, MD
Sponsor: Industrial

Title:  A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

COH Protocol Number: 15043 ClinicalTrials.gov Number: NCT02404220

Principal Investigator: Ibrahim Aldoss, MD
Sponsor: Industrial

Title:  A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

COH Protocol Number: 15041 ClinicalTrials.gov Number: NCT02401048

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Multi-Center Open-Label Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas

COH Protocol Number: 15032 ClinicalTrials.gov Number: NCT02258607

Principal Investigator: Marianna Koczywas, MD
Sponsor: Industrial

Title:  A Phase Ib Parallel Cohort Study Evaluating the Efficacy and Safety of Momelotinib and Momelotinib Combined with Trametinib in Subjects with Metastatic KRAS-mutated Non-Small Cell Lung Cancer(NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

COH Protocol Number: 15005 ClinicalTrials.gov Number: NCT00697632

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Open-Label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Patients with Advanced Malignancies

COH Protocol Number: 14352 ClinicalTrials.gov Number: NCT01915498

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation

COH Protocol Number: 14349 ClinicalTrials.gov Number: NCT02342782

Principal Investigator: Jasmine Zain, MD
Sponsor: Institutional

Title:  Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantion in Patients with Mature T-Cell Non-Hodgkin Lymphoma: the aTAC-BEAM Regimen

COH Protocol Number: 14332 ClinicalTrials.gov Number: NCT02261220

Principal Investigator: Warren Chow, MD
Sponsor: Industrial

Title:  A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors

COH Protocol Number: 14308 ClinicalTrials.gov Number: NCT02257567

Principal Investigator: Alex Herrera, MD
Sponsor: Industrial

Title:  A Phase IB/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS54501A)in Combination with Rituzimab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relpased or Refractory Follicular or Diffuse Large B-Cell Lymphoma

COH Protocol Number: 14301 ClinicalTrials.gov Number: NCT02270463

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

COH Protocol Number: 14299 ClinicalTrials.gov Number: NCT02301104

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients with Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.